Market revenue in 2023 | USD 9.7 million |
Market revenue in 2030 | USD 17.8 million |
Growth rate | 9% (CAGR from 2023 to 2030) |
Largest segment | Regenerative medicine |
Fastest growing segment | Drug Discovery & Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regenerative Medicine, Drug Discovery & Development |
Key market players worldwide | STEMCELL Technologies, CellGenix, PromoCell GmbH, Lonza Group Ltd, Celgene, Brainstorm Cell Therapeutics Inc, Osiris Therapeutics, Genea Biomedx, Takeda Pharmaceutical Co Ltd, Gamida Cell, Century Therapeutics Inc, MaxCyte Inc, Kite Pharma, Cellartis, Genea, Waisman Biomanufacturing, Bioheart |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to very small embryonic like stem cells market will help companies and investors design strategic landscapes.
Regenerative medicine was the largest segment with a revenue share of 90.72% in 2023. Horizon Databook has segmented the Italy very small embryonic like stem cells market based on regenerative medicine, drug discovery & development covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy very small embryonic like stem cells market , including forecasts for subscribers. This country databook contains high-level insights into Italy very small embryonic like stem cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account